DE69429608D1 - MHC-Klasse-II Transaktivator (CIITA) und dessen Anwendungen - Google Patents

MHC-Klasse-II Transaktivator (CIITA) und dessen Anwendungen

Info

Publication number
DE69429608D1
DE69429608D1 DE69429608T DE69429608T DE69429608D1 DE 69429608 D1 DE69429608 D1 DE 69429608D1 DE 69429608 T DE69429608 T DE 69429608T DE 69429608 T DE69429608 T DE 69429608T DE 69429608 D1 DE69429608 D1 DE 69429608D1
Authority
DE
Germany
Prior art keywords
genes
mhc class
proteins
ciita
transactivator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69429608T
Other languages
English (en)
Other versions
DE69429608T2 (de
Inventor
Prof Mach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novimmune SA
Original Assignee
Novimmune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune SA filed Critical Novimmune SA
Application granted granted Critical
Publication of DE69429608D1 publication Critical patent/DE69429608D1/de
Publication of DE69429608T2 publication Critical patent/DE69429608T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Laminated Bodies (AREA)
  • Credit Cards Or The Like (AREA)
  • Details Of Garments (AREA)
DE69429608T 1993-08-26 1994-08-26 MHC-Klasse-II Transaktivator (CIITA) und dessen Anwendungen Expired - Lifetime DE69429608T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93113665 1993-08-26

Publications (2)

Publication Number Publication Date
DE69429608D1 true DE69429608D1 (de) 2002-02-14
DE69429608T2 DE69429608T2 (de) 2002-09-12

Family

ID=8213211

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69429608T Expired - Lifetime DE69429608T2 (de) 1993-08-26 1994-08-26 MHC-Klasse-II Transaktivator (CIITA) und dessen Anwendungen

Country Status (6)

Country Link
EP (1) EP0648836B1 (de)
AT (1) ATE211763T1 (de)
DE (1) DE69429608T2 (de)
DK (1) DK0648836T3 (de)
ES (1) ES2170082T3 (de)
PT (1) PT648836E (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672473A (en) * 1994-08-24 1997-09-30 President And Fellows Of Harvard College Methods of identifying compounds useful for treating autoimmune diseases
FR2762327B1 (fr) * 1997-04-22 1999-07-02 Transgene Sa Sequence d'acide nucleique de genes ciita, susceptibles d'etre impliquees dans le controle et la regulation de l'expression de genes codant pour des molecules mhc de type ii et leur utilisation, notamment comme medicament
US6410261B2 (en) * 1997-11-06 2002-06-25 President And Fellows Of Harvard College CIITA-interacting proteins and methods of use therefor
FR2775003A1 (fr) 1998-02-19 1999-08-20 Transgene Sa Methode de criblage de composes capables d'inhiber la fixation entre le facteur de transcription stat1 et le facteur de transcription usf1
WO2003048371A2 (en) * 2001-12-07 2003-06-12 University Of Liverpool Dna vaccine
WO2004009801A1 (de) * 2002-07-19 2004-01-29 Genethor Gmbh Nicht antigen präsentierende zellen zur selektion von t-zellen
WO2004047860A2 (de) * 2002-11-28 2004-06-10 Genethor Gmbh Nicht antigen präsentierende, mhc ii exprimierende zellen zur unterdrückung von pathologischen immunreaktionen
WO2005049860A2 (en) * 2003-11-05 2005-06-02 Karolinska Innovations Ab Diagnostic and therapeutic methods and assays

Also Published As

Publication number Publication date
ATE211763T1 (de) 2002-01-15
DE69429608T2 (de) 2002-09-12
DK0648836T3 (da) 2002-04-22
EP0648836A1 (de) 1995-04-19
ES2170082T3 (es) 2002-08-01
PT648836E (pt) 2002-06-28
EP0648836B1 (de) 2002-01-09

Similar Documents

Publication Publication Date Title
ATE314482T1 (de) Rekombinante adenoviren-vektor und verfahren zur verwendung
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
DE69327645D1 (de) Dna-sequenzen kodierend für neuartige wachstums-/differentierungsfaktoren
WO1994001548A3 (en) Human nucleic acid fragments, isolated from brain adrenal tissue, placenta or bone narrow
DK0721506T3 (da) Bakterielle eksporterede proteiner og acellulære vacciner baseret derpå
DE69635207D1 (de) Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist.
DE69839444D1 (de) Smad 6 und dessen anwendungen
CY1112957T1 (el) Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου
CY1107552T1 (el) Ly6h γονιδιο
DE69429608D1 (de) MHC-Klasse-II Transaktivator (CIITA) und dessen Anwendungen
WO1997022695A3 (fr) Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
EP0763105A4 (de) Für ein fibroblasten-aktivierungsproteinkodierende nukleinsäure und verwendungen dafür
ATE228567T1 (de) Transformation von phaffia rhodozyma
PT815233E (pt) NOVAS CITOCINAS AVIÁRIAS E SEQUjNCIAS GENÉTICAS QUE AS CODIFICAM
EP0773290A3 (de) Proteinanaloge des LDL-Rezeptors und deren kodierende Gene
DE69839765D1 (de) Lage-1 tumor-assozierte nukleinsäuren
ATE140928T1 (de) Proteine, die die expression von vertebraten-mhc- klasse-ii-genen regulieren, dafür kodierende dna- sequenzen und pharmazeutische zusammensetzungen
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
DE69519654D1 (de) htFIIIA Gen
NO20011961D0 (no) PRV-1-genet og anvendelsen av dette
AU2002350406A1 (en) Identification of ses-3 (spr-5) in c. elegans and the uses of the same
AU2002314193A1 (en) Identification of ses-1 and the uses of the same
HUP9802046A2 (hu) Eljárás génmanipulációs úton létrehozott emberi omega-2 interferon, az ezt kódoló DNS-szekvencia és a fenti genetikai információt tartalmazó prokarióta, és eukarióta sejtek előállítására

Legal Events

Date Code Title Description
8364 No opposition during term of opposition